The author discusses how Principal Care Management (PCM) enhances oncology care, improves patient outcomes, and boosts ...

A novel image-based deep learning approach achieves high accuracy and interpretability, offering potential for clinical ...

Deepak L. Bhatt, MD, MPH, MBA, of Mount Sinai Fuster Heart Hospital, spoke at the recent ASPC 2025 Congress on CVD Prevention ...

FDA approved zopapogene imadenovec, the first therapy for recurrent respiratory papillomatosis, providing an option beyond ...

National Psoriasis Awareness Month offers an opportunity to examine how advances in systemic therapy, combined with ...

Given the track record of good outcomes and savings, policy leaders must do more to promote growth of for-profit PACE ...

Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American ...

Jonathan Thompson, MD, MS, emphasized that broader molecular testing in early-stage non–small cell lung cancer (NSCLC) is essential to guide perioperative treatment decisions, while selective ...

Health systems must prepare for the growing impact of cell and gene therapies by addressing their high costs, complex care pathways, and payer collaboration needs to ensure timely and sustainable ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy could not be established.

Despite nurses often being the first health care workers many patients encounter, they frequently lack adequate tools to optimally evaluate their patients’ conditions, as in the case with myasthenia ...

Today, the FDA issued a complete response letter (CRL) for vatiquinone (PTC Therapeutics), delaying its potential approval as a treatment for Friedreich ataxia amid efficacy concerns.